VIR
NASDAQVir Biotechnology Inc.
Price$9.97-0.20 (-1.97%)
01:30 PM07:45 PM
News · 26 weeks40+800%
2026-04-192026-10-11
Mix1890d
- SEC Filings6(33%)
- Other5(28%)
- Earnings2(11%)
- Insider2(11%)
- Leadership2(11%)
- Offering1(6%)
Latest news
25 items- SECSEC Form 8-K filed by Vir Biotechnology Inc.8-K - Vir Biotechnology, Inc. (0001706431) (Filer)
- PRVir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors- Collaboration combines Vir Biotechnology’s T-cell engager discovery, AI-enabled protein engineering and clinically-validated PRO-XTEN® masking technology with Gilead’s oncology development and commercialization expertise - This is the Company’s second collaboration building on the universal PRO-XTEN® masking technology Vir Biotechnology, Inc. (NASDAQ:VIR), today announced a collaboration and license agreement with Gilead to discover and engineer three novel PRO-XTEN® dual-masked T-cell engager (TCE) development candidates targeting selected solid tumor-associated antigens. Gilead will have an exclusive license to develop and commercialize the novel TCEs. Through this collaboration,
- SECSEC Form 8-K filed by Vir Biotechnology Inc.8-K - Vir Biotechnology, Inc. (0001706431) (Filer)
- PRVir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate CancerVir Biotechnology, Inc. (NASDAQ:VIR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN® dual-masked T-cell engager (TCE), for the treatment of late-line metastatic castration-resistant prostate cancer (mCRPC). VIR-5500 is being co-developed by Astellas Pharma Inc. and Vir Biotechnology through a global strategic collaboration. "Receiving Fast Track designation reflects the potential of VIR-5500 to address an area of serious unmet need in late-line mCRPC and the strong momentum we have achieved with Astellas as we prepare to enter pivotal Phase 3 development in 2027," said Marianne De Backer, President and
- PRVir Biotechnology Appoints David Liu as Chief Medical OfficerVir Biotechnology, Inc. (NASDAQ:VIR) today announced the appointment of David Liu, M.D., Ph.D., as Executive Vice President and Chief Medical Officer (CMO), effective October 12, 2026. Dr. Liu will be responsible for leading the clinical development, medical affairs and regulatory affairs functions. "David brings extensive immuno-oncology leadership experience, a strong track record of advancing and securing approvals for innovative cancer therapies and deep expertise in global regulatory strategy and execution," said Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology. "I look forward to partnering with him as we advance our Phase 3 program for chronic hepatitis d
- INSIDERSEC Form 3 filed by Vir Biotechnology Inc.3 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- PRVir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of elebsiran and tobevibart for chronic hepatitis delta at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026 in Denver, CO, November 5-9, 2026. Efficacy of elebsiran (VIR-2218) and tobevibart (VIR-3434) in participants with chronic hepatitis delta infection: Patterns of HDV RNA responses through Week 96 Format: Oral presentation Session: Hepatitis – Other Infections Presenter: Tarik Asselah Date: November 8, 2026 Time: 2:15 p.m. to 2:30 p.m. MT From inflammation to surveillance: Intrahepatic NK ce
- SECVir Biotechnology Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Vir Biotechnology, Inc. (0001706431) (Filer)
- PRVir Biotechnology Appoints Aziz Sawaf as Chief Financial OfficerVir Biotechnology, Inc. (NASDAQ:VIR) today announced the appointment of Aziz Sawaf, MBEE, MBA, CFA, as Executive Vice President and Chief Financial Officer (CFO), effective October 5, 2026. Mr. Sawaf will be responsible for leading the finance, IT and investor relations functions. "I am delighted to welcome Aziz to the executive leadership team. His experience in driving financial performance across the biotech lifecycle, from clinical development through regulatory approval and commercialization, will be a valuable asset for Vir Biotechnology’s next phase of growth," said Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology. "Aziz also brings a mindset of discip
- PRVir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceVir Biotechnology, Inc. (NASDAQ:VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, President and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14 at 7:45 a.m. ET in New York City, New York. A live webcast of the fireside chat will be available at https://investors.vir.bio and will be archived for 30 days. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes
- INSIDERDirector More Robert J disposed of 8,000 shares and acquired 8,000 shares, decreasing direct ownership by 16% to 40,656 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Vir Biotechnology Inc.SCHEDULE 13G - Vir Biotechnology, Inc. (0001706431) (Subject)
- SECSEC Form 10-Q filed by Vir Biotechnology Inc.10-Q - Vir Biotechnology, Inc. (0001706431) (Filer)
- SECVir Biotechnology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Vir Biotechnology, Inc. (0001706431) (Filer)
- PRVir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results- Phase 2 SOLSTICE data presented at the EASL Congress showed that elebsiran and tobevibart achieved undetectable HDV RNA in 88% of participants with chronic hepatitis delta (CHD) at Week 96 of treatment - Topline data from Phase 3 ECLIPSE 1 trial expected in the fourth quarter of 2026 - Closed global strategic collaboration with Astellas and initiated additional VIR-5500 Phase 1 monotherapy and combination therapy dose-expansion cohorts in patients with metastatic prostate cancer - Ended quarter with over $1.0 billion in cash, cash equivalents and investments - Conference call scheduled for August 5, 2026, at 4:30 p.m. ET / 1:30 p.m. PT Vir Biotechnology, Inc. (NASDAQ:VIR), today
- SECVir Biotechnology Inc. filed SEC Form 8-K: Leadership Update8-K - Vir Biotechnology, Inc. (0001706431) (Filer)
- PRVir Biotechnology Announces Chief Financial Officer TransitionVir Biotechnology, Inc. (NASDAQ:VIR) today announced that Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed Interim Principal Financial Officer, effective July 23. Jason O’Byrne is leaving the Company to pursue another opportunity and will remain with Vir Biotechnology through August 3 to ensure a smooth transition. The Company has initiated a comprehensive search to identify its next Chief Financial Officer."Brent has deep institutional knowledge and financial acumen and has played a significant role in our strategic business development efforts and latest public offering, which helped to establish a strong cash position for the Company," said Marianne D
- PRVir Biotechnology to Host Conference Call for Second Quarter 2026 Financial ResultsVir Biotechnology, Inc. (NASDAQ:VIR) today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 5 to provide a corporate update and discuss its financial results for the second quarter ended June 30, 2026. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website.About Vir BiotechnologyVir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T
- SECSEC Form 144 filed by Vir Biotechnology Inc.144 - Vir Biotechnology, Inc. (0001706431) (Subject)
- INSIDERDirector Coughlin Timothy was granted 16,000 units of Common Stock (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- INSIDERNew insider Coughlin Timothy claimed no ownership of stock in the company (SEC Form 3)3 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- SECVir Biotechnology Inc. filed SEC Form 8-K: Leadership Update8-K - Vir Biotechnology, Inc. (0001706431) (Filer)
- PRVir Biotechnology Announces Appointment of Timothy Coughlin to its Board of DirectorsVir Biotechnology, Inc. (NASDAQ:VIR) today announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. "We are pleased to welcome Tim to Vir Biotechnology's Board of Directors at a pivotal moment for the company," said Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, Vir Biotechnology. "Tim brings a strong background of strategic discipline and operational insight that has helped organizations evolve into fully integrated enterprises. His extensive experience as chief financial officer and board member spanning discovery through commercialization will be highly valuable as we advance our portfolio. We
- INSIDERDirector Napolitano Janet sold $30,240 worth of shares (3,200 units at $9.45) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 21,216 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- INSIDERSVP, Chief Accounting Officer Sabatini Brent sold $3,582 worth of Common Stock (379 units at $9.45) as part of a pre-agreed trading plan, decreasing direct ownership by 0.61% to 61,902 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
VIR FAQ
7 questionsWhat does Vir Biotechnology Inc. do?
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration...Where does VIR stock trade?
Vir Biotechnology Inc. (VIR) is listed on NASDAQ.What sector and industry is VIR in?
Vir Biotechnology Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Vir Biotechnology Inc. go public?
Vir Biotechnology Inc. (VIR) completed its IPO in 2019.What are analysts saying about VIR?
Vir Biotechnology Inc. has had 8 recent analyst actions on file. The most recent action was from Raymond James: Strong Buy with a $1900.00 price target on 2026-02-24. Recent price targets range from $900.00 to $3400.00.What companies are similar to VIR?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare VIR side-by-side with any of them on Quantisnow.How can I track VIR on Quantisnow?
Quantisnow aggregates Vir Biotechnology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VIR to receive live email and push alerts on every new disclosure.